We join the worldwide
Rare Disease Day celebrations

Watch the official rare disease day 2018 video


to go



We are a global specialty pharmaceutical company based in Switzerland committed to the research and development of medicines to meet the needs of patients living with mitochondrial disorders and other rare diseases.

Read more>>

About Mitochondrial Diseases

At Santhera, we are passionate about providing treatment options for patients with rare mitochondrial diseases, specifically in the area of neuromuscular and neuro-ophthalmological conditions – diseases that have a severe impact on the lives of affected children and adults.

Read more>>
Health Care Professionals

Our medicines

Our focus is on the development of treatments for neuromuscular and neuro-ophthalmological diseases that currently lack treatment options. In September 2015, we received our first European Marketing Authorization for Raxone® in the treatment of patients with Leber’s hereditary optic neuropathy.

Read more>>
Investors & Media

Tools and Resources

The Investor and Media center provides information and resources for investor and media communities.

Read more>>

Working @Santhera

Santhera is a dynamic and international employer looking for colleagues who are talented, engaged and committed to growing the organization through the work that they do.

Read more>>

Latest News

Earlier press releases can be found here.
To subscribe to our News Feed, please click here.